Exploration of the immunologic characteristics of KIT/PDGFRA wild-type gastrointestinal stromal tumor and potential application of neoantigen vaccination

The study has been reviewed and approved by the Institutional Review Board of Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School (No. 2021-027-02). According to the risk stratification of GIST,[7] 33 (23.24%) patients were classified as high-risk (stage IV). Generally, compared to KIT/PDGFRA mutant GISTs, WT-GISTs had higher gene mutation frequency in positive markers of immunotherapy (6.20% vs. 2.73%, for WT-GISTs vs. KIT/PDGFRA mutant GISTs, P = 0.001) and fewer gene mutations frequency in negative markers of immunotherapy (5.00% vs. 12.27%, for WT-GISTs vs.